Insulin glargine–lixisenatide

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Standard practice
Half-life: ~3 h; Approximate, in adults. Detail in 01.

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: insulin-glargine-lixisenatide · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Lixisenatide slows gastric emptying, which can delay or reduce absorption of oral psilocybin and add to nausea. The insulin component adds hypoglycemia risk with a light or skipped meal.

Human data with psilocybin: None known: no published human data with psilocybin
Common practice: GLP-1 receptor agonists slow gastric emptying, which can delay or reduce absorption of orally taken medicines, including psilocybin, and add to its nausea.
Half-life: Lixisenatide ~3 h (multiple dose) (FDA label, checked 2026-10-01)

Evidence types on this record

PrStandard practice; no psilocybin-specific data

02 Pharmacology relevant to psilocybin

2 listed · counted on reports

Slows gastric emptying: Slows how quickly the stomach empties. Can delay or change the onset of a dose taken by mouth and add to nausea. Sources [1]
Hypoglycemia risk: Can cause low blood sugar, especially if meals are missed or delayed. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Soliqua 100/33 · FDA label (DailyMed)

Report an error in this record →